AstraZeneca Pharma India received CDSCO approval on May 20, 2026, to import and market Calquence tablets for an additional indication.
The approval covers Acalabrutinib combination therapy for previously untreated mantle cell lymphoma patients ineligible for transplant.
Marketing in India for this new indication is subject to receipt of related statutory approvals.